Regeneron Pharmaceuticals (NasdaqGS: REGN) and Medivation (NasdaqGS: MDVN), BBH’s number 11 and number 12 holdings and almost a combined 8% of the ETF’s weight, also have cancer therapies. Medivation makes the prostate cancer treatment Xtandi while Regeneron makes Zaltrap, which is part of chemotherapy regimens.
Overall, 16 of BBH’s 26 holdings have oncology exposure. The 10 stocks in the ETF that do not combine for just 22% of the ETF’s weight. [Hot Healthcare ETFs]
With that, BBH is levered to biotech takeover talk because at least six of its holdings in addition to Pharmacyclics have been previously mentioned as potential targets.
Market Vectors Biotech ETF
